Document is current
Any future updates will be listed below
-
Authors
Leborgne, Christian
Barbon, Elena
Alexander, Jeffrey M. http://orcid.org/0000-0002-2258-5738
Hanby, Hayley
Delignat, Sandrine
Cohen, Daniel M. http://orcid.org/0000-0002-7963-668X
Collaud, Fanny http://orcid.org/0000-0002-2901-7290
Muraleetharan, Saghana
Lupo, Dan
Silverberg, Joseph
Huang, Karen http://orcid.org/0000-0001-6633-5776
van Wittengerghe, Laetitia
Marolleau, Béatrice
Miranda, Adeline
Fabiano, Anna http://orcid.org/0000-0002-7604-6967
Daventure, Victoria
Beck, Heena
Anguela, Xavier M.
Ronzitti, Giuseppe http://orcid.org/0000-0002-9184-0210
Armour, Sean M.
Lacroix-Desmazes, Sebastien http://orcid.org/0000-0001-5625-8447
Mingozzi, Federico http://orcid.org/0000-0003-0685-3752
- License Information
-
More Information
Article History
Received: 23 January 2020
Accepted: 27 April 2020
First Online: 1 June 2020
Competing interests
: J.M.A., H.H., S.M., D.L., J.S., K.H., D.M.C., H.B., X.M.A., S.M.A. and F.M. are employees of Spark Therapeutics, a Roche company. F.M., S.L.D., S.M.A. and C.L. are inventors on a patent related to this work. Patent applicants: Institut National de la Santé et de la Recherche Médicale; Généthon; Sorbonne Université; Université Paris Descartes; Université Paris Diderot; Spark Therapeutics. Inventors: S. Lacroix-Desmazes, F. Mingozzi, C. Leborgne, J. D. Dimitrov, S. M. Armour. Application no. PCT/EP2019/069280 (application request filed). Specific aspects of the manuscript covered in the patent application include use of IdeS to decrease pre-existing antibody immunity to AAV and allow for vector readministration.
